These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 21635149)

  • 1. Anthracycline cardiotoxicity.
    Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.
    Zerra P; Cochran TR; Franco VI; Lipshultz SE
    Expert Opin Pharmacother; 2013 Aug; 14(11):1497-513. PubMed ID: 23705955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.
    Minotti G; Menna P; Salvatorelli E; Cairo G; Gianni L
    Pharmacol Rev; 2004 Jun; 56(2):185-229. PubMed ID: 15169927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
    Menna P; Minotti G; Salvatorelli E
    Cell Biol Toxicol; 2007 Jan; 23(1):49-62. PubMed ID: 17031515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC; Caron HN; Kremer LC
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity and cardioprotection in childhood cancer.
    Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
    Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
    Ky B; Carver JR
    Heart Fail Clin; 2011 Jul; 7(3):323-31. PubMed ID: 21749884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiotoxicity of anthracyclines: mechanisms and pharmacologic targets for prevention].
    Andrieu-Abadie N
    Therapie; 2004; 59(1):121-6. PubMed ID: 15199678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline cardiotoxicity: from bench to bedside.
    Gianni L; Herman EH; Lipshultz SE; Minotti G; Sarvazyan N; Sawyer DB
    J Clin Oncol; 2008 Aug; 26(22):3777-84. PubMed ID: 18669466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer agents and cardiotoxicity.
    Ng R; Better N; Green MD
    Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart's content.
    Oliveira GH; Al-Kindi SG; Caimi PF; Lazarus HM
    Blood Rev; 2016 May; 30(3):169-78. PubMed ID: 26578029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ranolazine in the prevention of anthracycline-related cardiotoxicity].
    Corradi F; Paolini L; De Caterina R
    G Ital Cardiol (Rome); 2013 Jun; 14(6):424-37. PubMed ID: 23748539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New iron chelators in anthracycline-induced cardiotoxicity.
    Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
    Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.